1
|
Moore KM, Thomas GJ, Duffy SW, Warwick J, Gabe R, Chou P, Ellis IO, Green AR, Haider S, Brouilette K, Saha A, Vallath S, Bowen R, Chelala C, Eccles DM, Tapper WJ, Thompson AM, Quinlan P, Jordan LB, Gillet C, Brentall A, Violette S, Weinreb P, Kendrew J, Barry ST, Hart IR, Jones JL, Marshall JF. Abstract P4-15-01: Integrin avb6 is a therapeutic target for high-risk breast cancer and enhances trastuzumab efficacy. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The integrin avβ6 promotes migration, invasion and survival of cancer cells, but the biological relevance has yet to be ascertained in breast cancer. Our immunhistochemical analysis of over 2000 breast cancers has revealed that high expression of the protein for the integrin subunit beta6 (β6) is associated with very poor survival (HR = 1.99, P = 2.9×10-6) and increased metastases to distant sites (P = 0·02). This correlation was confirmed at the mRNA level via bioinformatic analysis of the 2000 women in the METABRIC cohort. Furthermore, co-expression of HER2 gave a significantly worse prognosis (HR = 3.43, P = 4×10-12), which we investigated further.
We report from in vitro studies that HER2-driven invasion is mediated by αvβ6 in an Akt2-dependent manner. Using the well-tolerated αvβ6-blocking antibody 264RAD in vivo we show that antibody-blockade of this integrin suppressed growth of BT-474 and MCF-7/HER2-18 human breast cancer xenografts similarly to trastuzumab alone (P<0.001), the antibody used for treating HER2-positive cancers (both 10mg/kg, bi-weekly). Moreover, when 264RAD was co-administered it significantly enhanced the ability of trastuzumab to suppress BT-474 tumor growth with a reduction in mean tumor volume of 94.8%+/-1.18% compared to 70.8%+/-5.98% observed with trastuzumab alone (P<0.0001) after 2 weeks treatment. This trend was reproduced even in the MCF-7/HER2-18 trastuzumab-resistant breast cancer tumors where a 76.24%+/-10.15% reduction was observed with combination therapy (P<0.0001) compared with only 44.62%+/-10.43% (P = 0.0006) and 46.6%+/-14.71% (P = 0.0004) reductions in final volume with 264RAD and trastuzumab respectively. The combination therapy was so effective it almost eradicated 100mm3 BT-474 tumors and completely eliminated small (10-20mm3) MCF-7/HER2-18 tumors.
264RAD or trastuzumab prolonged survival to a similar degree (14.3% and 33.33% treated mice alive after 100d, respectively, no significant difference) but again, when both drugs were combined 85.7% of mice were alive after 100d, a highly significant response compared with PBS (P<0.0001) or monotherapies (264RAD: P<0.0001, trastuzumab: P<0.0001). Post-therapy biochemistry revealed residual tumors expressed significantly reduced αvβ6, HER2, HER3 and downstream signaling molecules including Akt2 and Smad2, essentially a much lower ‘grade’ tumour.
Since 70% of women treated with trastuzumab either have, or develop resistance, we suggest combined targeting of αvβ6 and HER2 could provide an important novel therapy for thousands of women with breast cancer. In fact, over 39,000 American women annually (NIH statistics) will develop HER2+ breast cancers for which no specific therapies exist. Our data shows that in excess of 40% of these women with trastuzumab-resistant disease are also likely to express high levels of αvβ6.
Our data also suggest that routine determination of the level of expression of αvβ6 on breast cancers would be a valuable clinical tool as it identifies novel high-risk groups of women that require enhanced therapeutic intervention.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-15-01.
Collapse
Affiliation(s)
- KM Moore
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - GJ Thomas
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - SW Duffy
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - J Warwick
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - R Gabe
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - P Chou
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - IO Ellis
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - AR Green
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - S Haider
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - K Brouilette
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - A Saha
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - S Vallath
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - R Bowen
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - C Chelala
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - DM Eccles
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - WJ Tapper
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - AM Thompson
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - P Quinlan
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - LB Jordan
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - C Gillet
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - A Brentall
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - S Violette
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - P Weinreb
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - J Kendrew
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - ST Barry
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - IR Hart
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - JL Jones
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| | - JF Marshall
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Southampton General Hospital, Southampton, United Kingdom; Nottingham City Hospital NHS Trust, Nottingham, United Kingdom; Ninewells Hospital and Medical School, Dundee, United Kingdom; Hedley Atkins Breast Pathology, Guy's Hospital, London, United Kingdom; Biogen Idec, Cambridge; AstraZeneca-Medimmune, Macclesfield, United Kingdom
| |
Collapse
|
2
|
Moore KM, Hart IR, Jones LJ, Marshall JF. P2-01-05: Integrin avb6 Mediates HER2−Driven Invasion in Breast Cancer. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
We have shown strong expression of integrin αvβ6 reduces the 5 year survival of HER2−positive breast cancers from 66% (HR 1.84) for moderate/low αvβ6 expressors to 54% (HR 2.18) in cases with strong expression (2063 cases, unpublished). This is in direct comparison to HER2/αvβ6-double negative cases, where strong αvβ6 expression reduces survival from 86% (HR 1.00) to 77% (HR 1.20). The biological mechanism underlying these observations was investigated in two isogenic breast cancer models: MCF-7/neo-1 and MCF-7/HER2−18 (a gift from Prof. M-C. Hung, USA) and MCF10A and MCF10A.CA1a.
Flow cytometry showed MCF-7/HER2−18 expressed high levels of both HER2 and αvβ6 whereas MCF-7/neo-1 expressed low levels of both receptors. MCF10A and MCF10A.CA1a both expressed high levels of αvβ6 whereas only MCF10A.CA1a expressed elevated levels of HER2. In charcoal-stripped (cs)-serum, comparing MCF-7/neo-1 and MCF-7/HER2−18, HRGβ1(1μM), which stimulates HER2/HER3 heterodimers, increased proliferation by 50.2%±9% (P=0.048) and 66.2%±5.5% (P=0.003), in MCF-7/neo-1 and MCF-7/HER2−18 cells respectively. In contrast, Herceptin reduced proliferation by 32.3%±13.4% (P=0.003) and 15.2%±3.4% (P=0.028), respectively. MCF10A and MCF10A.CA1a proliferation remained unchanged with HRGβ 1 treatment and antibody-blockade of αvβ6 did not affect proliferation of any cell line. (NB, in complete serum there was no effect on proliferation of any of the above treatments). Invasion through Matrigel of MCF-7/HER2−18 was inhibited by antibody blockade (10μg/ml) of αvβ6 (mAb 10D5; 38.6%±20.8%, P=0.005) or HER2 (Herceptin, 10μg/ml; 40.1%±28.6%, P=0.01). The same trend was observed in MCF10A.CA1a invasion (83%±30.2% (P=0.025) with 10D5 and 80.4%±8.7% (P=0.022) with Herceptin). Combination of both antibodies had no additional effect.
siRNA knockdown of αvβ6 or HER2 in MCF-7/HER2−18 and MCF10A.CA1a cells also reduced invasion to a similar extent as the blocking antibodies. This suggests that HER2 driven breast carcinoma invasion is mediated by αvβ6. To investigate this further HER2/3 was stimulated with HRGβ1, which consistently increased invasion by 111.5%±35.4% (P=0.011) in MCF-7/HER2−18 cells and by 57%±34% (P=0.042) in MCF10A.CA1a cells; an increase that was abrogated by co-treatment with 10D5 or Herceptin.
To determine the mechanism through which HER2 and αvβ6 co-operate we examined several signalling pathways. Analysis of total or activated Akt, ERKI/II, c-Jun or Src in the MCF-7 model showed no changes. However, elevated total and phospho-Stat3 in MCF-7/HER2−18 were observed and siRNA knockdown, or small-molecule inhibition, of Stat3 suppressed invasion of MCF-7/HER2−18 cells (54.5%±27.3% (P=0.008) and 55.3%±33.3% (P=0.01) respectively), possibly suggesting that activation of Stat3 may link αvβ6 and HER2 co-operative signalling in this model. Interestingly, Akt was constitutively phosphorylated in MCF10A.CA1a cells and, moreover, 10D5 reduced these levels suggesting αvβ6 may influence HER2 signalling via Akt in these cells.
These data confirm HER2−driven invasion is αvβ6-mediated and provide a mechanistic explanation for our clinical observations. We suggest HER2 and αvβ6 should be considered as dual targets for future therapy of some breast cancers.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-01-05.
Collapse
Affiliation(s)
- KM Moore
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| | - IR Hart
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| | - LJ Jones
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| | - JF Marshall
- 1Barts Cancer Institute -a CR-UK Centre of Excellence, Queen Mary University of London, London, Greater London, United Kingdom
| |
Collapse
|
3
|
Abstract
BACKGROUND AND AIMS Pancreatic cancer is a highly invasive malignancy. Ezrin, a plasma membrane-cytoskeletal linker protein, is associated with the invasive behaviour of cancers. The purpose of this study was to elucidate a possible molecular mechanism for the invasive phenotype. METHODS Using a combination of techniques, such as western blotting, co-immunoprecipitation, confocal and light microscopy, invasion and adhesion assays, organotypic cultures and human samples as well as RNA interference (RNAi) and expression of various mutant ezrin constructs, the dynamic molecular nature of podosomes in pancreatic cancer was dissected out. RESULTS Podosome and podosomal rosette formation in pancreatic carcinoma (PaCa3) cells is ezrin dependent and associated with adhesion to fibronectin with subsequent digestion of this substrate. Ezrin binds to increasing amounts of cortactin during formation of the podosomal rosette, with the C-terminal region, specifically the actin-binding domain, mediating this molecular linkage. Further, it is shown that phosphorylation of Tyr353 and Thr567 sites on ezrin (conventionally shown to translocate ezrin to the plasma membrane) is not required for podosome formation. The podosomal rosette is revealed to be a highly dynamic and transient structure, which can metamorphose into other cellular processes, such as filopodia or lamellipodia, and thereby enable epithelial cancer cells to "palpate" the underlying substrate and modify their cytoskeletal behaviour accordingly. In human tumour tissues and organotypic cultures, specific subcellular expression of ezrin (basal membranous; cellular processes invading stroma) in pancreatic cancer cells can be correlated with tumour progression and disease-free survival (log-rank test (Mantel-Cox), p = 0.019). CONCLUSION Podosomes and their rosettes are driven by ezrin-cortactin interaction and this plays a role in pancreatic cancer invasion.
Collapse
Affiliation(s)
- H M Kocher
- Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Barts & The London School of Medicine & Dentistry, John Vane Science Centre, London, UK.
| | | | | | | | | |
Collapse
|
4
|
Duffy SW, Bowen RL, Ryan DA, Hart IR, Jones JL. Reply: Early onset of breast cancer in black British women: how reliable are the findings? Br J Cancer 2008. [PMCID: PMC2538757 DOI: 10.1038/sj.bjc.6604626] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
5
|
Lai-Cheong JE, Ussar S, Arita K, Hart IR, McGrath JA. Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome. J Invest Dermatol 2008; 128:2156-65. [PMID: 18528435 PMCID: PMC2628768 DOI: 10.1038/jid.2008.58] [Citation(s) in RCA: 72] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Kindler syndrome (KS) results from pathogenic loss-of-function mutations in the KIND1 gene, which encodes kindlin-1, a focal adhesion and actin cytoskeleton-related protein. How and why abnormalities in kindlin-1 disrupt keratinocyte cell biology in KS, however, is not yet known. In this study, we identified two previously unreported binding proteins of kindlin-1: kindlin-2 and migfilin. Co-immunoprecipitation and confocal microscopy studies show that these three proteins bind to each other and colocalize at focal adhesion in HaCaT cells and normal human keratinocytes. Moreover, loss-of-function mutations in KIND1 result in marked variability in kindlin-1 immunolabeling in KS skin, which is mirrored by similar changes in kindlin-2 and migfilin immunoreactivity. Kindlin-1, however, may function independently of kindlin-2 and migfilin, as loss of kindlin-1 expression in HaCaT keratinocytes by RNA interference and in KS keratinocytes does not affect KIND2 or FBLIM1 (migfilin) gene expression or kindlin-2 and migfilin protein localization. In addition to identifying protein-binding partners for kindlin-1, this study also highlights that KIND1 gene expression and kindlin-1 protein labeling are not always reduced in KS, findings that are relevant to the accurate laboratory diagnosis of this genodermatosis by skin immunohistochemistry.
Collapse
Affiliation(s)
- J E Lai-Cheong
- Genetic Skin Disease Group, St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London, London, UK
| | | | | | | | | |
Collapse
|
6
|
|
7
|
Abstract
Since there are no published data on breast cancer in British black women, we sought to determine whether, like African-American women, they present at a younger age with biologically distinct disease patterns. The method involved a retrospective review of breast cancer to compare age distributions and clinicopathological features between black women and white women in the UK, while controlling for socioeconomic status. All women presented with invasive breast cancer, between 1994 and 2005, to a single East London hospital. Black patients presented significantly younger (median age of 46 years), than white patients (median age of 67 years (P=0.001)). No significant differences between black and white population structures were identified. Black women had a higher frequency of grade 3 tumours, lymph node-positive disease, negative oestrogen receptor and progesterone receptor status and basal-like (triple negative status) tumours. There were no differences in stage at presentation; however, for tumours of ⩽2 cm, black patients had poorer survival than white patients (HR=2.90, 95% CI 0.98–8.60, P=0.05). Black women presented, on average, 21 years younger than white women. Tumours in younger women were considerably more aggressive in the black population, more likely to be basal-like, and among women with smaller tumours, black women were more than twice as likely to die of their disease. There were no disparities in socioeconomic status or treatment received. Our findings could have major implications for the biology of breast cancer and the detection and treatment of the disease in black women.
Collapse
Affiliation(s)
- R L Bowen
- Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Barts and The London, Queen Mary's School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK.
| | | | | | | | | |
Collapse
|
8
|
Nyström ML, Thomas GJ, Stone M, Mackenzie IC, Hart IR, Marshall JF. Development of a quantitative method to analyse tumour cell invasion in organotypic culture. J Pathol 2005; 205:468-75. [PMID: 15685705 DOI: 10.1002/path.1716] [Citation(s) in RCA: 120] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Tumour invasion is a dynamic process occurring in three dimensions and involving interactions between both tumour and stromal cells. Experimental analysis of squamous carcinoma cell invasion has often used the organotypic gel culture system, which is generated by plating tumour cells on to a synthetic stroma composed of a collagen gel embedded with fibroblasts. Unfortunately, quantitation of invasion in these organotypic gels has relied largely on subjective pathological opinion, which may be influenced by different patterns of tumour cell infiltration. Therefore a computer-assisted digital image analysis system that assesses invasion objectively and provides a numerical 'Invasion Index' was developed. The Invasion Index, by combining depth and pattern of invasion in a single value, establishes a quantitative value that allows assessment of the influences of positive and negative regulation of tumour invasion. These data demonstrate that the organotypic gel system is a robust, accurate, and reproducible method for measuring tumour cell invasion. They also show that the Invasion Index can be used after organotypic gels have been implanted in mice for up to 6 weeks. Illustrative examples of how various factors influence the invasion of squamous carcinoma cells in three dimensions both in vitro and in vivo are provided.
Collapse
Affiliation(s)
- M L Nyström
- Tumour Biology Laboratory, Cancer Research UK Clinical Centre, Queen Mary's School of Medicine and Dentistry at Barts and the London, London, UK.
| | | | | | | | | | | |
Collapse
|
9
|
Thomas GJ, Hart IR, Speight PM, Marshall JF. Binding of TGF-beta1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer 2002; 87:859-67. [PMID: 12373600 PMCID: PMC2376166 DOI: 10.1038/sj.bjc.6600545] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2002] [Revised: 07/08/2002] [Accepted: 07/23/2002] [Indexed: 01/08/2023] Open
Abstract
The integrin alpha(v)beta6 is not detectable on normal keratinocytes in vivo but expression is increased significantly in oral squamous cell carcinoma where this heterodimer has been shown to play a role in cell migration, invasion and protease expression. Although regarded initially as a fibronectin receptor, alpha(v)beta6 may bind to arginine-glycine-aspartic acid sequences in other matrix molecules including tenascin and vitronectin. Interestingly, alpha(v)beta6 has also been shown to have high affinity for the TGF-beta1 latency associated peptide and to participate in the activation of the TGF-beta1 latent complex. Since TGF-beta1 is present in squamous carcinomas, it is possible that latency associated peptide may modulate malignant keratinocyte behaviour independently from the classical TGF-beta signalling pathways through its interaction with integrins. We show here that when latency associated peptide is immobilised onto a surface, it acts as an alpha(v)beta6-specific ligand for oral squamous carcinoma cells promoting adhesion and haptotactic migration in addition to alpha(v)beta6-dependent increase in pro-MMP-9 expression. In contrast, even very low concentrations of soluble latency associated peptide (0.1 microg ml(-1)) inhibited alpha(v)beta6-dependent adhesion, migration and invasion. Thus alpha(v)beta6-dependent processes of oral squamous cell carcinoma, is likely to be modulated, not only by the local concentration of latency associated peptide in the stroma, but also whether it is immobilised in the matrix or released as a soluble protein.
Collapse
Affiliation(s)
- G J Thomas
- Department of Oral Pathology, Eastman Dental Institute, University College London, UK
| | | | | | | |
Collapse
|
10
|
Townsend PA, Dublin E, Hart IR, Kao RH, Hanby AM, Cutress RI, Poulsom R, Ryder K, Barnes DM, Packham G. BAG-i expression in human breast cancer: interrelationship between BAG-1 RNA, protein, HSC70 expression and clinico-pathological data. J Pathol 2002; 197:51-9. [PMID: 12081204 DOI: 10.1002/path.1081] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BAG-1 (BCL-2 athanogene-1), a multifunctional protein which associates with steroid hormone receptors (including the oestrogen receptor) and the anti-apoptotic BCL-2 protein, regulates steroid hormone-dependent transcription and apoptosis. Direct interaction with 70 kD heat-shock proteins, HSC70 and HSP70, may mediate the diverse functions of BAG-1. Immunohistochemistry was used to examine the expression of BAG-1 and HSC70 in 160 cases of invasive breast cancer. BAG-1 was expressed in 92% of cases; most tumours exhibited cytoplasmic BAG-1, while a smaller proportion also had nuclear immunostaining. There was a significant inverse correlation between histological grade and nuclear BAG-1 expression, with higher-grade tumours tending to have reduced nuclear BAG-1 expression, but there was no association with cytoplasmic BAG-1. There was also no significant correlation between nuclear or cytoplasmic BAG-1 expression and oestrogen receptor positivity. Since BAG-1 may be influenced by hormonal background, the relationship between grade and oestrogen receptor was examined separately in pre-menopausal and post-menopausal women. The statistically significant correlation between nuclear BAG-1 expression and low tumour grade was strong in pre-menopausal, but not apparent in postmenopausal women. A statistically significant correlation was observed between cytoplasmic, but not nuclear, BAG-1 expression and oestrogen receptor status in pre-menopausal, but not postmenopausal, women. There was no correlation between BAG-1 protein expression and RNA, suggesting that important post-transcriptional mechanisms control BAG-1 expression in vivo. HSC70 was also detected in the majority (97%) of cases, although expression was not correlated with BAG-1 levels, oestrogen receptor status or tumour grade. Overall survival in cases with high levels of nuclear BAG-1 expression was improved, though not significantly. These results are consistent with the hypothesis that BAG-1 plays an important but variable role in breast cancers developing in pre-menopausal and post-menopausal women.
Collapse
Affiliation(s)
- P A Townsend
- Cancer Sciences Division, School of Medicine, University of Southampton, Southampton General Hospital, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
The introduction of new learning technologies, the exponential growth of Internet usage and the advent of the World Wide Web have the potential of changing the face of higher education. There are also demands in medical education for greater globalization, for the development of a common core curriculum, for improving access to training, for more flexible and student-centred training programmes including programmes with multi-professional elements and for maintaining quality while increasing student numbers and working within financial constraints. An international virtual medical school (IVIMEDS) with a high-quality education programme embodying a hybrid model of a blended curriculum of innovative e-learning approaches and the best of traditional face-to-face teaching is one response to these challenges. Fifty leading international medical schools and institutions are participating in a feasibility study. This is exploring: innovative thinking and approaches to the new learning technologies including e-learning and virtual reality; new approaches to curriculum planning and mapping and advanced instructional design based on the use of 'reusable learning objects'; an international perspective on medical education which takes into account the trend to globalization; a flexible curriculum which meets the needs of different students and has the potential of increasing access to medicine.
Collapse
Affiliation(s)
- R M Harden
- Centre for Medical Education, University of Dundee, UK.
| | | |
Collapse
|
12
|
Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol 2001; 195:191-6. [PMID: 11592098 DOI: 10.1002/path.941] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Intracellular hyaluronic acid binding protein (RHAMM/IHABP), which was recently identified as a novel member of the microtubule-associated protein (MAP) family, has the capacity to interact not only with microtubules but also with microfilaments. The molecule, which is known to be expressed in mammary carcinoma cells, might, through virtue of its intracellular interactions, influence tumour cell morphology and motility. This possibility was examined in a series of 189 mammary carcinomas by immunohistochemistry, using a polyclonal antibody to RHAMM/IHABP. Tumours were selected to include approximately equal numbers of consecutive grade I, II and III ductal carcinomas and invasive lobular carcinomas. Higher grade tumours had significantly lower expression of RHAMM/IHABP in the cytoplasm (p=0.02), but significantly increased expression in trabeculae (p=0.002) and further enhancement at the tumour island edges (p=0.002). Tumours of infiltrating lobular type had stronger expression in the overall cytoplasm (p=0.02) and trabeculae (p=0.08) than carcinomas of ductal type. The presence of strong trabecular expression was associated with a reduced overall survival time (p=0.017). These results suggest that RHAMM/IHABP expression may contribute to the motility and invasiveness of a tumour cell sub-population in breast cancers.
Collapse
Affiliation(s)
- V Assmann
- Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund Laboratory, St. Thomas' Hospital, London SE1 7EH, UK
| | | | | | | | | | | |
Collapse
|
13
|
|
14
|
Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR, Speight PM, Marshall JF. Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 2001; 117:67-73. [PMID: 11442751 DOI: 10.1046/j.0022-202x.2001.01379.x] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The integrin alphavbeta6 is a fibronectin receptor whose expression is not detectable on normal oral epithelium but is increased significantly in healing and in oral epithelial dysplasia and oral squamous cell carcinoma, suggesting it may promote changes associated with tumor development. To study whether alphavbeta6 may drive invasive behavior we have used transfection and retroviral infection to create a panel of epithelial cell lines expressing various levels of alphavbeta6. We report that increased expression of alphavbeta6 in malignant keratinocytes promotes invasion and leads to an increased capacity for migration towards fibronectin. alphavbeta6 expression may have a significant role in contributing to the malignant behavior of epithelial cells.
Collapse
Affiliation(s)
- G J Thomas
- Department of Oral Pathology, Eastman Dental Institute, University College London, UK
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
The integrin alphaVbeta6 is a fibronectin receptor, which is not detectable on normal epithelium but is neo-expressed in oral epithelial dysplasia and oral squamous-cell carcinoma (SCC), suggesting a role in promoting malignant behaviour and tumour progression. We used transfection and retroviral infection to create a panel of SCC cell lines expressing various levels of alphaVbeta6 to examine this possibility. We found that increased expression of alphaVbeta6 in malignant keratinocytes up-regulates MMP-9 and MMP-2 expression and promotes invasion in an MMP-9-dependent manner. Our results suggest a possible mechanism for the involvement of alphaVbeta6 in squamous carcinoma in vivo.
Collapse
Affiliation(s)
- G J Thomas
- Department of Oral Pathology, Eastman Dental Institute, University College London, 256 Gray's Inn Road, London WC1X 8L6, United Kingdom
| | | | | | | | | |
Collapse
|
16
|
Thomas GJ, Poomsawat S, Lewis MP, Hart IR, Speight PM, Marshall JF. alpha v beta 6 Integrin upregulates matrix metalloproteinase 9 and promotes migration of normal oral keratinocytes. J Invest Dermatol 2001; 116:898-904. [PMID: 11407978 DOI: 10.1046/j.1523-1747.2001.01352.x] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The integrin alpha v beta 6 is a fibronectin receptor that is undetectable on normal keratinocytes in situ, but is increased significantly in wound healing and in culture-established keratinocytes, suggesting that it may promote changes associated with cell motility. Using normal human oral keratinocytes we have shown that cultured cells express relatively high levels of alpha v beta 6 and this integrin has a functional role in both cell adhesion and migration towards fibronectin. We provide experimental evidence that the increased expression of alpha v beta 6 by normal human oral keratinocytes results in coordinate changes, which promote a more migratory phenotype. Thus increased expression of alpha v beta 6 results in a fibronectin-dependent increase in pro-matrix metalloproteinase 9, matrix metalloproteinase 9 activity increases normal human oral keratinocyte migration, and this may be further dependent on plasmin activation. The results suggest a key role for alpha v beta 6 in these processes and indicate a coordinated link between alpha v beta 6 expression and upregulation of matrix metalloproteinase 9. It appears that alpha v beta 6 may function in normal human oral keratinocyte migration through matrix-metalloproteinase-9-dependent and -independent mechanisms.
Collapse
Affiliation(s)
- G J Thomas
- Department of Oral Pathology, Eastman Dental Institute, University College London, UK
| | | | | | | | | | | |
Collapse
|
17
|
Thomas GJ, Lewis MP, Hart IR, Marshall JF, Speight PM. AlphaVbeta6 integrin promotes invasion of squamous carcinoma cells through up-regulation of matrix metalloproteinase-9. Int J Cancer 2001. [PMID: 11340566 DOI: 10.1002/1097-0215(20010601)92:] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The integrin alphaVbeta6 is a fibronectin receptor, which is not detectable on normal epithelium but is neo-expressed in oral epithelial dysplasia and oral squamous-cell carcinoma (SCC), suggesting a role in promoting malignant behaviour and tumour progression. We used transfection and retroviral infection to create a panel of SCC cell lines expressing various levels of alphaVbeta6 to examine this possibility. We found that increased expression of alphaVbeta6 in malignant keratinocytes up-regulates MMP-9 and MMP-2 expression and promotes invasion in an MMP-9-dependent manner. Our results suggest a possible mechanism for the involvement of alphaVbeta6 in squamous carcinoma in vivo.
Collapse
Affiliation(s)
- G J Thomas
- Department of Oral Pathology, Eastman Dental Institute, University College London, 256 Gray's Inn Road, London WC1X 8L6, United Kingdom
| | | | | | | | | |
Collapse
|
18
|
Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 2001; 92:404-8. [PMID: 11291078 DOI: 10.1002/ijc.1208] [Citation(s) in RCA: 187] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The cell-cell adhesion receptor gene E-cadherin (CDH1) is expressed by epithelial cells, in which it mediates adhesion and morphogenesis. Invasive lobular carcinoma (ILC) characteristically infiltrates diffusely as single cells; by immunohistochemistry, many of these tumours lack E-cadherin expression. In the present study we investigated various ways in which loss of function of the E-cadherin gene could occur in ILCs, namely, promoter methylation, mutation and allelic loss. We analysed 22 ILCs and found 12 (55%) E-cadherin-negative samples by immunohistochemical analysis. Methylation-specific polymerase chain reaction (PCR) showed that 17/22 (77%) of these tumours had methylation of the CDH1 promoter, including 11/12 (91%) of the E-cadherin-negative tumours. All 16 exons of E-cadherin (including intron-exon boundaries) were amplified from chromosomal DNA and screened for mutations by conformation-sensitive gel electrophoresis (CSGE). Bands with altered mobility were analysed by direct sequencing. We identified five frameshift mutations, which resulted in downstream stop codons and one splice site mutation in six different tumours (29%). Loss of heterozygosity (LOH) was assessed using microsatellite markers, and 9/18 (50%) informative tumours showed LOH. We conclude that most ILCs show genetic or epigenetic changes affecting the E-cadherin gene and that many of these tumours lack E-cadherin expression. In all cases in which there was loss of expression, this was consistent with biallelic inactivation of CDH1 by promoter methylation, mutation or allelic loss in any combination.
Collapse
Affiliation(s)
- S Droufakou
- Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund, Rayne Institute, St. Thomas' Hospital, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
19
|
Thorne RF, Marshall JF, Shafren DR, Gibson PG, Hart IR, Burns GF. The integrins alpha3beta1 and alpha6beta1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J Biol Chem 2000; 275:35264-75. [PMID: 10956645 DOI: 10.1074/jbc.m003969200] [Citation(s) in RCA: 72] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Lateral association between different transmembrane glycoproteins can serve to modulate integrin function. Here we characterize a physical association between the integrins alpha(3)beta(1) and alpha(6)beta(1) and CD36 on the surface of melanoma cells and show that ectopic expression of CD36 by CD36-negative MV3 melanoma cells increases their haptotactic migration on extracellular matrix components. The association was demonstrated by co-immunoprecipitation, reimmunoprecipitation, and immunoblotting of surface-labeled cells lysed in Brij 96 detergent. Confocal microscopy illustrated the co-association of alpha(3) and CD36 in cell membrane projections and ruffles. A requirement for the extracellular domain of CD36 in this association was shown by co-immunoprecipitation experiments using surface-labeled MV3 melanoma or COS-7 cells that had been transiently transfected with chimeric constructs between CD36 and intercellular adhesion molecule 1 (ICAM-1) or with a truncation mutant of CD36. CD36 is known to engage in signal transduction and to localize to membrane microdomains or rafts in several cell types. Toward a mechanistic explanation for the functional effects of CD36 expression, we demonstrate that in fractionated Triton X-100 lysates of the MV3 cells stably transfected with CD36, CD36 was greatly enriched with the detergent-insoluble fractions that represent plasma membrane rafts. Significantly, when these fractionated lysates were reprobed for endogenous beta(1) integrin, it was found that a 4-fold increase in the proportion of the mature protein was contained within the detergent-insoluble fractions when extracted from the CD36-transfected cells compared with MV3 cells transfected with vector only. These results suggest that in melanoma cells CD36 expression may induce the sequestration of certain integrins into membrane microdomains and promote cell migration.
Collapse
Affiliation(s)
- R F Thorne
- Cancer Research Unit and Department of Microbiology, Faculty of Medicine and Health Sciences, University of Newcastle, New South Wales 2308, Australia.
| | | | | | | | | | | |
Collapse
|
20
|
Abstract
Polymorphic epithelial mucin (PEM), the protein product of the gene muc-1, is a surface glycoprotein that is produced by a range of normal epithelial cells, but has been shown to be expressed at high levels in a range of adenocarcinomas. It has not been investigated extensively in head and neck related tissues, and not at all in head and neck squamous cell carcinomas (HNSCC). This immunohistochemical investigation using two monoclonal antibodies to muc-1 represents a baseline study of 18 HNSCC. In 13 cases, the glycoprotein was expressed at varying levels, usually in keratinizing foci. Although less prominent, expression was also present to some degree in nine of 23 control specimens of non-neoplastic mucosa, mostly at an epithelial level early in the parakeratinization process. Both antibodies showed a pattern of staining. The cellular basis for muc-1 expression is speculative at present and although it is at a lower level than in adenocarcinomas, it may help to provide further insight into epithelial cell differentiation in squamous cell carcinomas.
Collapse
Affiliation(s)
- J S Rubin
- Institute of Laryngology and Otology, Royal National Throat, Nose and Ear Hospital, London, UK
| | | | | | | |
Collapse
|
21
|
Seller Z, Hart IR. Investigation of signal transduction pathways involved in melanoma cell spreading. Indian J Exp Biol 2000; 38:211-21. [PMID: 10927861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Integrins are a major family of heterodimeric adhesion receptors that are responsible for anchoring cells to extracellular matrix and they also can initiate intracellular signal pathways. Here parental and alpha 4-expressing human malignant melanoma cell lines were used to study the effect of protein kinase C (PKC), protein tyrosine kinases (PTKs) and intracellular Ca2+ on alpha 4 beta 1-mediated cell spreading on VCAM-1. Incubation of melanoma cells with PKC inhibitor inhibited alpha 4 beta 1-mediated melanoma cell spreading completely. Effect of intracellular Ca2+ on melanoma cell spreading was also investigated by non-phorbol ester tumor promotor, thapsigargin, which blocks the ability of the endoplasmic reticulum to replenish stocks of calcium which naturally leak out into the cytosol leading to a transient increase in concentration of intracellular calcium. The results showed that alpha 4 beta 1-mediated spreading was also required intracellular calcium involvement. However, in the presence of PTKs inhibitor melanoma cells showed long, thin dendiritic projections compared to control cells. Previously, data was obtained from immunofluorescense experiments showed that after genistein treatment, alpha 4-expressing cells exhibited considerable amounts of alpha 4 integrin and PTKs in both the focal contact points as well as over the whole cell. PTKs inhibitor did not have any effect on alpha 4-expressing cells spreading. This could be related to the amount of the PTKs present in these cells.
Collapse
Affiliation(s)
- Z Seller
- University of Anatolia, Department of Pharmacology, Eskisehir, Turkey.
| | | |
Collapse
|
22
|
von Schlippe M, Marshall JF, Perry P, Stone M, Zhu AJ, Hart IR. Functional interaction between E-cadherin and alphav-containing integrins in carcinoma cells. J Cell Sci 2000; 113 ( Pt 3):425-37. [PMID: 10639330 DOI: 10.1242/jcs.113.3.425] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
We have demonstrated the possibility of cross-talk between E-cadherin and alphav integrins in breast carcinoma cells. Using the function-blocking anti-alphav monoclonal antibody 17E6, applied to monolayer cultures of breast cancer lines, it was found that treatment of cells possessing detergent-insoluble (implying attachment to the actin cytoskeleton) E-cadherin resulted in the adoption of a spheroid configuration of cell growth. This effect was dependent upon not just alphav occupancy but also receptor aggregation. Thus in vitro alphav-dependent adhesion suppresses E-cadherin-mediated morphological changes. To investigate whether manipulation of E-cadherin would, conversely, modulate integrin activity we introduced a dominant-negative E-cadherin construct into one of the lines, ZR75-1, giving rise to the cell line ZR-E2R1. Surface expression of endogenous E-cadherin was downregulated (by around 25%), whereas beta-catenin levels were increased two- to threefold in ZR-E2R1 cells. There was also a highly significant increase in migration of ZR-E2R1 cells (relative to control cells) toward vitronectin (P<0.001), but not toward collagen type I, fibronectin or laminin. Such increased migration could be abrogated totally by antibody blockade of alphavbeta5 and alphavbeta1 integrins. There was no detectable change in alphav integrin levels. These data suggest that the introduction of a dominant-negative E-cadherin mutant into ZR75-1, in addition to a loss of cohesion, generates a signal (or signals) which increases migration towards vitronectin through increased activity of alphav integrins.
Collapse
Affiliation(s)
- M von Schlippe
- Richard Dimbleby Department of Cancer Research, Imperial Cancer Research Fund, Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK
| | | | | | | | | | | |
Collapse
|
23
|
Assmann V, Jenkinson D, Marshall JF, Hart IR. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci 1999; 112 ( Pt 22):3943-54. [PMID: 10547355 DOI: 10.1242/jcs.112.22.3943] [Citation(s) in RCA: 120] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We reported recently on the intracellular localisation of the hyaluronan receptor RHAMM/IHABP in human cancer cells. Here we describe the colocalisation of RHAMM/IHABP proteins with microtubules, both in interphase and dividing cells, suggesting that RHAMM/IHABP represents a novel member of the family of microtubule-associated proteins (MAPs). We have identified four different splice variants of RHAMM/IHABP, all of which colocalise, at least transiently, with microtubules when expressed as GFP fusion proteins in HeLa cells. Using microtubule-binding assays and transient transfection experiments of deletion-bearing RHAMM/IHABP mutants, we localised the microtubule-binding region to the extreme N terminus of RHAMM/IHABP. This interaction domain is composed of two distinct subdomains, one of which is sufficient to mediate binding to the mitotic spindle while both domains are required for binding of RHAMM/IHABP proteins to interphase microtubules. Sequence analysis revealed that the projection domain of RHAMM/IHABP is predicted to form coiled-coils, implying that RHAMM/IHABP represents a filamentous protein capable of interacting with other proteins and we found that RHAMM/IHABP interacts with actin filaments in vivo and in vitro. Moreover, in vitro translated RHAMM/IHABP isoforms efficiently bind to immobilised calmodulin in a Ca(2+)-dependent manner via a calmodulin-binding site within the projection domain of RHAMM/IHABP (residues 574–602). Taken together, our results strongly suggest that RHAMM/IHABP is a ubiquitously expressed, filamentous protein capable of interacting with microtubules and microfilaments and not, as numerous previous reports suggest, a cell surface receptor for the extracellular matrix component hyaluronan.
Collapse
Affiliation(s)
- V Assmann
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK.
| | | | | | | |
Collapse
|
24
|
Abstract
Minimal residual disease (MRD), the tumour burden which remains after a course of treatment that has resulted in clinical remission [1], appears to differ in certain characteristics from the primary tumour population. Certainly the cells which comprise MRD have had to escape from the constraints of the primary tumour mass, invade normal tissue and penetrate small vessels in order to enter the circulation in which they then have had to survive. Such activities are the consequence of the expression of specific proteins and these may well be a reflection of alterations in DNA or RNA levels. Identifying the changes in RNA expression levels between related cell groups exhibiting different phenotypes recently has become a great deal easier as a consequence of developments in analytical procedures such as Differential Display (DD) and Serial Analysis of Gene Expression (SAGE). Application of these procedures to MRD cells recovered from blood, bone marrow or lymph node, should identify novel sequences associated with tumour progression and the development of disseminated disease.
Collapse
Affiliation(s)
- R H Kao
- Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund, Rayne Institute, St. Thomas' Hospital, London, UK
| | | | | | | | | |
Collapse
|
25
|
Issenberg SB, Petrusa ER, McGaghie WC, Felner JM, Waugh RA, Nash IS, Hart IR. Effectiveness of a computer-based system to teach bedside cardiology. Acad Med 1999; 74:S93-S95. [PMID: 10536605 DOI: 10.1097/00001888-199910000-00051] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Affiliation(s)
- S B Issenberg
- Center for Research in Medical Education, University of Miami School of Medicine, FL 33101, USA
| | | | | | | | | | | | | |
Collapse
|
26
|
Issenberg SB, McGaghie WC, Hart IR, Mayer JW, Felner JM, Petrusa ER, Waugh RA, Brown DD, Safford RR, Gessner IH, Gordon DL, Ewy GA. Simulation technology for health care professional skills training and assessment. JAMA 1999; 282:861-6. [PMID: 10478693 DOI: 10.1001/jama.282.9.861] [Citation(s) in RCA: 514] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Changes in medical practice that limit instruction time and patient availability, the expanding options for diagnosis and management, and advances in technology are contributing to greater use of simulation technology in medical education. Four areas of high-technology simulations currently being used are laparoscopic techniques, which provide surgeons with an opportunity to enhance their motor skills without risk to patients; a cardiovascular disease simulator, which can be used to simulate cardiac conditions; multimedia computer systems, which includes patient-centered, case-based programs that constitute a generalist curriculum in cardiology; and anesthesia simulators, which have controlled responses that vary according to numerous possible scenarios. Some benefits of simulation technology include improvements in certain surgical technical skills, in cardiovascular examination skills, and in acquisition and retention of knowledge compared with traditional lectures. These systems help to address the problem of poor skills training and proficiency and may provide a method for physicians to become self-directed lifelong learners.
Collapse
Affiliation(s)
- S B Issenberg
- Center for Research in Medical Education, University of Miami School of Medicine, FL 33101, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Francia G, Poulsom R, Hanby AM, Mitchell SD, Williams G, Mckee P, Hart IR. Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells. Int J Cancer 1999; 82:709-13. [PMID: 10417769 DOI: 10.1002/(sici)1097-0215(19990827)82:5<709::aid-ijc14>3.0.co;2-r] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We described the occurrence of 4 transcripts differentially displayed between syngeneic murine B16F10 (metastatic melanoma) and Melan-a (immortalised melanocytes) cell lines. We now report that one such transcript, which is B16F10-specific, represents a protein phosphatase-2A B' regulatory subunit. No expression of this transcript was detected in the weakly metastatic B16F1 by Northern blotting. Moreover, the transcript was not expressed by spontaneously immortalised, non-tumorigenic, melanocytes (Melan-Ab and Melan-a2), nor was it expressed by ras-transformed, tumourigenic melanocytes (Melan-Ab-LTR-ras). Cloning of the 5'-end region of this transcript (termed band 8A) from B16F10 cells revealed an intracisternal A-particle insertion, including the long terminal repeat region, which could account for the observed high expression in B16F10 cells. Single cell clones of B16F10 manifested an experimental metastasis capacity, which correlated with band 8A expression with the lowest expressors being least metastatic. The human homologue of the B' regulatory subunit, B56gamma, is expressed preferentially at the mRNA level in human melanoma cell lines compared with normal epidermal melanocytes. In situ hybridisation studies on human clinical samples detected high expression of this gene in a number of malignant melanomas. Our results imply strongly that this protein phosphatase-2A regulatory subunit may have a role in melanoma tumour progression.
Collapse
Affiliation(s)
- G Francia
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, The Rayne Institute, UMDS, St. Thomas' Hospital, London, UK
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
There is a need to move from opinion-based education to evidence-based education. Best evidence medical education (BEME) is the implementation, by teachers in their practice, of methods and approaches to education based on the best evidence available. It involves a professional judgement by the teacher about his/her teaching taking into account a number of factors-the QUESTS dimensions. The Quality of the research evidence available-how reliable is the evidence? the Utility of the evidence-can the methods be transferred and adopted without modification, the Extent of the evidence, the Strength of the evidence, the Target or outcomes measured-how valid is the evidence? and the Setting or context-how relevant is the evidence? The evidence available can be graded on each of the six dimensions. In the ideal situation the evidence is high on all six dimensions, but this is rarely found. Usually the evidence may be good in some respects, but poor in others.The teacher has to balance the different dimensions and come to a decision on a course of action based on his or her professional judgement.The QUESTS dimensions highlight a number of tensions with regard to the evidence in medical education: quality vs. relevance; quality vs. validity; and utility vs. the setting or context. The different dimensions reflect the nature of research and innovation. Best Evidence Medical Education encourages a culture or ethos in which decision making takes place in this context.
Collapse
|
29
|
Abstract
There is a need to move from opinion-based education to evidence-based education. Best evidence medical education (BEME) is the implementation, by teachers in their practice, of methods and approaches to education based on the best evidence available. It involves a professional judgement by the teacher about his/her teaching taking into account a number of factors-the QUESTS dimensions. The Quality of the research evidence available-how reliable is the evidence? the Utility of the evidence-can the methods be transferred and adopted without modification, the Extent of the evidence, the Strength of the evidence, the Target or outcomes measured-how valid is the evidence? and the Setting or context-how relevant is the evidence? The evidence available can be graded on each of the six dimensions. In the ideal situation the evidence is high on all six dimensions, but this is rarely found. Usually the evidence may be good in some respects, but poor in others.The teacher has to balance the different dimensions and come to a decision on a course of action based on his or her professional judgement.The QUESTS dimensions highlight a number of tensions with regard to the evidence in medical education: quality vs. relevance; quality vs. validity; and utility vs. the setting or context. The different dimensions reflect the nature of research and innovation. Best Evidence Medical Education encourages a culture or ethos in which decision making takes place in this context.
Collapse
|
30
|
Abstract
Tumour latency, or dormancy, is a well-recognized clinical phenomenon and induction or maintenance of this state would appear to offer a novel therapeutic approach to limiting the effects of neoplastic disease. Current interest has focused on the role that neovascularization plays in this process and the consequences of shifts in the balance between angiogenic and anti-angiogenic peptides. Targeting tumour vasculature by the administration or induction of such anti-angiogenic peptides is close to clinical evaluation.
Collapse
Affiliation(s)
- I R Hart
- Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund, Rayne Institute, St Thomas' Hospital, London, U.K.
| |
Collapse
|
31
|
Hofmann M, Assmann V, Fieber C, Sleeman JP, Moll J, Ponta H, Hart IR, Herrlich P. Problems with RHAMM: a new link between surface adhesion and oncogenesis? Cell 1998; 95:591-2; author reply 592-3. [PMID: 9845361 DOI: 10.1016/s0092-8674(00)81628-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- M Hofmann
- Forschungszentrum Karlsruhe and University of Karlsruhe, Institutes of Genetics, Germany
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Geng L, Ali SA, Marshall JF, Mackay CL, Hart IR, Delcommence M, Streuli CH, Rees RC. Fibronectin is chemotactic for CT 26 colon carcinoma cells: sub-lines selected for increased chemotaxis to fibronectin display decreased tumorigenicity and lung colonization. Clin Exp Metastasis 1998; 16:683-91. [PMID: 10211981 DOI: 10.1023/a:1006572526520] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
CT 26 murine colon carcinoma cells demonstrated directional migration (chemotaxis) in response to fibronectin (FN). Sub-lines were derived by positive and negative selection to FN across Transwell filters of 8 microm pore size. The FL6 sub-line (positively selected) demonstrated a significantly increased chemotactic response (P<0.01) to FN compared with parental CT 26 cells, while the FU7 sub-line (negatively selected) showed a reduced chemotactic response to FN (P<0.01). Comparable levels of alpha4, alpha5, alphav and beta1 integrins, which mediate FN attachment, were expressed on positively and negatively selected sub-lines and parental CT 26 cells. Activation of integrins with Mn2+ suggested that the integrins expressed on FL6 cells were in the fully activated state; in contrast FU7 cells displayed only partially activated integrins. Cell attachment and integrin activation status of the sub-lines correlated with their chemotactic response to FN. In vivo FL6 cells showed a significantly reduced tumour growth rate s.c. and a reduction in the number of lung colonies formed following i.v. injection compared with parental CT 26 and FU7 cells. In contrast FU7 cells displayed a significant increase in s.c. tumour growth and the number of lung colonies when compared with the parental line and FL6 sub-line. The results indicate that interaction between integrin receptors expressed on cancer cells and FN plays a central role in the chemotactic response of CT 26 colon carcinoma cells, and that in this model cells selected for chemotaxis to FN displayed a reduced malignant potential.
Collapse
Affiliation(s)
- L Geng
- Department of Life Sciences, Nottingham Trent University, UK
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Chong H, Hutchinson G, Hart IR, Vile RG. Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T-cell-dependent systemic immunity only against B7-expressing tumours. Br J Cancer 1998; 78:1043-50. [PMID: 9792148 PMCID: PMC2063155 DOI: 10.1038/bjc.1998.625] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
In an attempt to enhance the anti-tumour immune response, the co-stimulatory molecules B7-1 or B7-2 were expressed on the surface of B16 melanoma cells. B7-expressing tumours grew more slowly in both syngeneic immunocompetent mice and athymic T cell-immunodeficient nude mice. The delay in growth of B7-expressing tumours was dependent on natural killer (NK) cells, as reductions in tumour growth rates were minimized in mice depleted of NK cells. Systemic immunity to B16 melanoma was examined by vaccination with irradiated tumour cells. Inoculation with irradiated B16 B7-1 cells failed to protect against a subsequent challenge with live parental B16 cells, but conferred partial protection against challenge with live B16 B7-1 cells. In contrast to the local anti-tumour reaction, this protective response was dependent on T cells. The results presented here reveal some of the mechanisms involved in the in vivo response to a poorly immunogenic tumour modified to express co-stimulatory molecules.
Collapse
Affiliation(s)
- H Chong
- Department of Histopathology, United Medical and Dental Schools of Guy's and St. Thomas's Hospitals, London, UK
| | | | | | | |
Collapse
|
34
|
Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG. Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther 1998; 5:869-79. [PMID: 9813657 DOI: 10.1038/sj.gt.3300690] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
To develop protocols for the molecular immunotherapy of colorectal cancer, we compared the efficacy of three separate classes of therapeutic genes to induce antitumour responses in a murine colorectal cell model. Thus, the effects of two cytokines (IL-2 and GM-CSF) were compared with those of a costimulatory gene (B7.1) and a suicide gene (HSVtk). The rank order of efficacy against primary tumour growth was HSVtk[GCV], B7.1 > puro, IL-2 > GM-CSF, neo whereas the order of efficacy in inducing antitumour immunity was GM-CSF, IL-2, > B7.1, HSVtk[GCV] > puro, neo in a prophylactic vaccination model. To exploit these data in a clinically relevant and realistic way, we also demonstrated that colorectal tumours can reproducibly be explanted and established in short-term culture. Finally, a rapid transduction protocol has been developed by which, using adenoviral vectors, as many as 90% of the cells in these fresh tumour explants can be engineered to express high levels of the clinically relevant genes (GM-CSF or IL-2) within 1-2 weeks of surgery. Adenovirus-mediated gene delivery was reproducibly and significantly more efficient than retroviral transduction using the MFG-beta-Gal retroviral vector over the time-frame of importance for vaccination. Hence, combination of the animal model data with the ex vivo modification protocol suggests that vaccination of colorectal patients of the appropriate stage will be possible and effective.
Collapse
Affiliation(s)
- R M Diaz
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, Rayne Institute, St Thomas' Hospital, London, UK
| | | | | | | | | | | | | |
Collapse
|
35
|
Assmann V, Marshall JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci 1998; 111 ( Pt 12):1685-94. [PMID: 9601098 DOI: 10.1242/jcs.111.12.1685] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The receptor for hyaluronan mediated motility (RHAMM) has been reported to mediate migration, transformation, and metastatic spread of murine fibroblasts. Here we describe the expression of two human RHAMM isoforms, which are generated by alternative splicing of the primary gene transcript, by a series of human breast carcinoma cell lines. A polyclonal antibody, raised against a bacterially expressed RHAMM fusion protein, detected an 85–90 kDa protein by western blot analysis. No correlation between the level of RHAMM mRNA and protein expression with known metastatic/malignant potential of the tumour cell lines was observed. Interestingly, we found that the antibody did not stain the cell surface but the cytoplasm of breast cancer cells. The intracellular localisation of RHAMM was confirmed by subcellular fractionation studies. RHAMM proteins were capable of binding to hyaluronan, but not to heparin or chondroitin sulphate, in an vitro binding assay. We also provide evidence that a potential hyaluronan-binding motif in the N terminus of the protein is not involved in the interaction of RHAMM with hyaluronan. Our findings lead us to conclude that RHAMM does not function as a conventional motility receptor for HA in human breast cancer cells and we suggest the term RHAMM be substituted by ‘intracellular hyaluronic acid binding protein’ (IHABP).
Collapse
Affiliation(s)
- V Assmann
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK.
| | | | | | | | | |
Collapse
|
36
|
Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998; 77:1799-805. [PMID: 9667649 PMCID: PMC2150343 DOI: 10.1038/bjc.1998.299] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
The effects of acute hypoxia on integrin expression and adhesion to extracellular matrix proteins were investigated in two human melanoma cell lines, HMB-2 and DX3, and a human adenocarcinoma cell line, HT29. Exposure to hypoxia caused a significant down-regulation of cell surface integrins and an associated decrease in cell adhesion. Loss of cell adhesion and integrin expression were transient and levels returned to normal within 24 h of reoxygenation. Other cell adhesion molecules, such as CD44 and N-CAM, were also down-regulated after exposure of cells to hypoxia. Acute exposure to hypoxia of cells at confluence caused rapid cell detachment. Cell detachment preceded loss of viability. Detached HMB-2 and DX3 cells completely recovered upon reoxygenation, and floating cells re-attached and continued to grow irrespective of whether they were left in the original glass dishes or transferred to new culture vessels, while detached HT29 cells partly recovered upon reoxygenation. Cell detachment after decreased adhesion appears to be a stress response, which may be a factor enabling malignant cells to escape hypoxia in vivo, with the potential to form new foci of tumour growth.
Collapse
Affiliation(s)
- N M Hasan
- Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, UK
| | | | | | | | | |
Collapse
|
37
|
Cockett MI, Murphy G, Birch ML, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998; 63:295-313. [PMID: 9513731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The rationale for matrix metalloproteinase (MMP) inhibition as a means to treat disease progression in breast cancer stems from the apparent involvement of MMPs in the hydrolysis of basement membranes during tumour cell invasion and subsequent metastasis. MMP-mediated matrix remodelling also appears to promote the growth of tumour cells, possibly by facilitating the proliferation and migration of endothelial cells and the neovascularization of tumour tissue. We found that transfection of the C127 breast cancer cell line by MMP-2 (gelatinase A), but not by MMP-1 or MMP-3 (collagenase and stromelysin respectively), gave rise to an invasive and metastatic phenotype. We were surprised to find that this phenotype depended not only on the catalytic properties of MMP-2 but also on properties associated with the MMP-2 non-catalytic C-terminal domain. Experiments with a synthetic gelatinase inhibitor revealed that a single dose could prevent the lungs of nude mice being colonized by the MMP-2 transfectants, and that the inhibitor had to be administered during or shortly after injection of the cells, indicating that an early event, such as the extravasation of the cells into the lung, is gelatinase-dependent in this system. In other studies employing long-term treatment with CT1746, an orally active gelatinase inhibitor, we have previously demonstrated a reduction in primary tumour growth rates, localized spread, and spontaneous metastasis, even when the treatment was commenced several days after tumour implantation. Furthermore, additive effects were recorded when gelatinase inhibitor therapy was combined with cytotoxic drug treatment. Since the gelatinase inhibitors can also inhibit bone resorption in vitro, these observations point to their potential for delaying disease recurrence and reducing rates of bone loss following conventional therapeutic strategies, in metastatic breast cancer.
Collapse
Affiliation(s)
- M I Cockett
- Strangeways Research Laboratory, Cambridge, U.K
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
In the present study we have used fluorocytometry and immunoprecipitation to characterize the expression of alphav-containing integrins in a panel of eight human breast cancer cell lines and one normal human mammary epithelial line. We show that the classical vitronectin receptor alphavbeta3 is expressed in only one cell line (MDA-MB-231), whereas alphavbeta5 is expressed on all breast cancer cell lines and alphavbeta1 is expressed on the majority. Using adherence assays to purified ligands in the presence and absence of function-blocking monoclonal antibodies, we have demonstrated that alphavbeta5 mediates adhesion to vitronectin in the majority of these cells. In one cell line, ZR75-1, alphavbeta1 contributes significantly to adhesion to immobilized vitronectin. The formation of focal adhesions containing the alphav and beta1 subunits on vitronectin is also demonstrated by indirect immunofluorescence.
Collapse
Affiliation(s)
- T Meyer
- Richard Dimbleby Department of Cancer Research, St Thomas' Hospital, London, UK
| | | | | |
Collapse
|
39
|
Affiliation(s)
- T Meyer
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, St Thomas' Hospital, London, U.K
| | | |
Collapse
|
40
|
Chong H, Todryk S, Hutchinson G, Hart IR, Vile RG. Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther 1998; 5:223-32. [PMID: 9578842 DOI: 10.1038/sj.gt.3300584] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Previously, we showed that expression of B7-1 in CMT93 murine colorectal tumour cells inhibited their growth in immunocompetent animals. However, this did not result in any significant increase in systemic protective immunity, relative to that elicited by the parental tumour. To potentiate the effects of B7-1 on systemic immunity. Interleukin-12 (IL-12) or granulocyte-macrophage colony-stimulating factor (GM-CSF) was co-expressed with this molecule. These combinations of immunostimulatory molecules were effective in eliciting systemic immunity. We also show that expression of B7-2 led to a local antitumour response as well as significantly raised systemic immunity. In another tumour model. K1735 minutes melanoma, which is moderately immunogenic, tumours secreting GM-CSF alone were as effective as the parental tumours in generating protective immunity. Previously, we described the deleterious effect of B7-1 expression on protective immunity. Co-expression of GM-CSF did not counteract this consequence of B7-1 expression. Expression of IL-12 was extremely effective in causing rejection of inoculated tumour cells, but evoked only minimal protective systemic immunity. These results suggest that combing costimulatory molecules and cytokines may be a useful therapeutic approach in some, but not all, tumours.
Collapse
Affiliation(s)
- H Chong
- Division of Histopathology, United Medical and Dental School of Guy's and St Thomas' Hospital, London, UK
| | | | | | | | | |
Collapse
|
41
|
Marshall JF, Rutherford DC, Happerfield L, Hanby A, McCartney AC, Newton-Bishop J, Hart IR. Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas. Br J Cancer 1998; 77:522-9. [PMID: 9484806 PMCID: PMC2149935 DOI: 10.1038/bjc.1998.85] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Changes in integrin expression have been shown to be important for the growth and metastatic capacity of melanoma cells. In this study, we have examined the expression of alphav integrins by three uveal and four cutaneous malanoma lines. No lines expressed alphavbeta6 and only TXM13, a cutaneous line, expressed alphavbeta8. All lines expressed alphavbeta5 and alphavbeta3 (four out of four cutaneous, two out of three uveal) or avpl (OM431, an uveal line). Thus, OM431 is the second uveal melanoma we have described that expresses alphavbeta1 and this, we report again, functions as an alternative vitronectin/fibronectin receptor. Subcutaneous growth of cell lines in athymic mice correlated with an alphavbeta3-positive, alphavbeta1 -negative phenotype. Analysis of clinical material from cutaneous melanoma showed that although alphav expression was increased in 88% of metastases, this could not all be explained by up-regulation of alphavbeta3, with only 2 out of eight skin metastases expressing this heterodimer. Using antibody SZ.21, which as we report here works in archival material, only 1 out of 15 uveal metastases expressed detectable beta3. Thus, acquisition of alphavbeta3 expression, which has been implicated in cutaneous melanoma progression, may not be required for development of metastases from uveal melanoma or indeed for skin, as distinct from lymph node, metastases of cutaneous melanoma.
Collapse
Affiliation(s)
- J F Marshall
- Richard Dimbleby Department of Cancer Research, Rayne Institute, St Thomas' Hospital, London
| | | | | | | | | | | | | |
Collapse
|
42
|
Diaz RM, Eisen T, Hart IR, Vile RG. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol 1998; 72:789-95. [PMID: 9420288 PMCID: PMC109437 DOI: 10.1128/jvi.72.1.789-795.1998] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/1997] [Accepted: 09/24/1997] [Indexed: 02/05/2023] Open
Abstract
To generate transcriptionally targeted vectors, tissue-specific elements of the human tyrosinase promoter were exchanged with corresponding viral elements in the Moloney murine leukemia virus long terminal repeat (LTR). From these experiments, a vesicular stomatitis virus type G pseudotyped, hybrid LTR vector that contained three tyrosinase enhancer elements and gave high-level, tightly tissue-specific expression at high titers (3 x 10(7) CFU/ml) was constructed.
Collapse
Affiliation(s)
- R M Diaz
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, Rayne Institute, St. Thomas' Hospital, London, United Kingdom
| | | | | | | |
Collapse
|
43
|
Abstract
The metastatic spread of solid tumours is responsible directly or indirectly for most cancer-related deaths. Our understanding of the molecular genetic and biological events that contribute to tumor cell dissemination has increased considerably over the last decade. It is clear that close anatomic and temporal co-operation between cellular adhesion molecules, extracellular matrix (ECM)-degrading proteases and peptides inducing tumour vascularisation are essential components of the metastatic behaviour of cancer cells. Although this enhanced understanding may have little immediate impact on patient survival (about 50% of patients have established metastatic disease at first presentation), it has led to the development of novel anti-metastatic therapies targeting distinct molecules and steps in the metastatic cascade. Here we review the role of matrix-degrading enzymes, changes in cellular adhesive capacity and tumour angiogenesis during cancer spread, highlighting areas that are of emerging importance in the clinic.
Collapse
Affiliation(s)
- A Ahmad
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, Rayne Institute, UMDS, St. Thomas' Hospital, London, UK
| | | |
Collapse
|
44
|
Castleden SA, Chong H, Garcia-Ribas I, Melcher AA, Hutchinson G, Roberts B, Hart IR, Vile RG. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther 1997; 8:2087-102. [PMID: 9414257 DOI: 10.1089/hum.1997.8.17-2087] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The herpes simplex virus-thymidine kinase/ganciclovir (HSVtk/GCV) system produces both direct and immune-mediated tumor cell killing. Here, we compare the efficacy of HSVtk/GCV with cytokines, alone and in combination, on the tumorigenicity and immunogenicity of B16 cells. With respect to single gene modifications, only HSVtk/GCV, or high-level interleukin-2 (IL-2) secretion, completely prevented tumor growth, whereas granulocyte-macrophage colony-stimulating factor (GM-CSF) generated the best levels of long-term systemic protection. To augment both local killing and immune activation, we constructed bicistronic constructs that express HSVtk and a cytokine within the same cell. Co-expression of HSVtk with IL-2 or GM-CSF enhanced the local antitumor activity of any gene alone. In a tumor-prevention model, HSVtk killing, in an environment preprimed with GM-CSF, generated the best long-term immune protection. However, in a short-term therapy model, continued IL-2 expression was most effective against 3-day established tumors. This probably reflects differences in the activities of IL-2 and GM-CSF in generating short-term, nonspecific immune stimulation compared to long-term immunological memory, respectively. As a prelude to in vivo delivery experiments, we also demonstrated that these bicistronic cassettes can be packaged normally into retroviral (5 x 10(5) virus/ml from pooled populations) and adenoviral vectors (5 x 10(9) virus/ml) and function as predicted within virally infected cells. This family of bicistronic vectors can be used to stimulate synergy between suicide and cytokine genes, overcomes the problems of delivering two genes on separate vectors, and should allow easier preparation of vectors for the delivery of multiple genes to patients' tumor cells.
Collapse
Affiliation(s)
- S A Castleden
- Imperial Cancer Research Fund Laboratory of Molecular Therapy, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
We have examined the functional status of the VLA-4/alpha4beta1 integrin in a panel of human melanoma cell lines, focusing on the ability of cells expressing alpha4beta1 to mediate adhesion to the alpha4-specific ligands CS-1 peptide and VCAM-1. All melanoma cells expressing alpha4pbeta1 (8 of 10 lines examined) were capable of adhering to these specific ligands in adhesion assays, whereas 2 cell lines (HMB2 and VUP) which lacked surface alpha4 were unable to do so. Adherence of different melanoma cell lines to VCAM-1 was relatively uniform and not susceptible to upregulation with known integrin-activating factors, such as manganese ions, phorbol ester and activating monoclonal antibody (mAb) TS2/16. Cell adhesion to CS-1 peptide, however, varied according to cell surface receptor density and, in some cases, could be up-regulated by integrin-activating factors. Adhesion of SK23 cells to CS-1 peptide was increased by all 3 activating stimuli, whereas for all other melanoma cells an increase was obtained only by the use of TS2/16 mAb. Our data indicate not only an unusually low activation state of alpha4beta1 in SK23 cells but also heterogeneity in the activating capacity of the various stimuli. Moreover, a protein kinase C-dependent role in alpha4beta1 activity was suggested by adhesion assays carried out in the presence of the protein kinase C inhibitor calphostin C, which considerably reduced adhesion to CS-1 peptide.
Collapse
Affiliation(s)
- A Saini
- Richard Dimbleby Department of Cancer Research/ICRF Laboratory, St. Thomas' Hospital, London, UK
| | | | | | | | | |
Collapse
|
46
|
Abstract
The matrix-degrading enzyme family of matrix-metalloproteinases (MMPs) has been implicated in the process of tumour metastasis. Cellular protein and RNA localisation techniques have been used to show that, whilst several MMP genes are expressed in both cancer and stromal cells, stromelysin 3 is expressed only in stromal fibroblasts adjacent to cancer cells. Immunohistochemical and in situ hybridisation evidence suggests that neoplastic cells can stimulate stromal cell MMP production either in a paracrine fashion or by a cell-cell contact mechanism. Using 2 different lengths of the human stromelysin 3 (ST3) gene 5' flanking sequence cloned upstream of luciferase and CAT reporter genes, we now show that human breast cancer cells can directly activate the ST3 promoter. The putative response element in the ST3 promoter, which lies between 0.46 and 3.4 kb upstream of the transcription start site, is able to effect a 2- to 3-fold increase in downstream gene expression. We further show that this transcriptional up-regulation definitely occurs via a paracrine, and possibly via a cell-cell contact, mechanism. Confirmation that this ST3 promoter activation results in ST3 gene induction of a similar magnitude was shown using Northern blotting of stimulated fibroblasts. Our data provide further evidence that cancer cells can induce fibroblast MMP expression and help to explain the in vivo expression pattern of ST3 in breast cancer.
Collapse
Affiliation(s)
- A Ahmad
- Division of Oncology, United Medical and Dental School, London, UK.
| | | | | | | | | |
Collapse
|
47
|
Abstract
Adenovirus internalization generally has been accepted to involve an interaction of the adenoviral penton base protein with alpha(v)beta3 and alpha(v)beta5 cell surface integrins. In this study we show that exposure of a panel of melanoma cells to the beta1-activating antibody TS2/16 rendered such cells more susceptible to adenovirus infection. This increase in adenoviral infectivity paralleled effects on cell adhesion, and both these characteristics were mediated, in part, by the alpha5beta1 integrin. These observations suggest that alpha5beta1 may act as an alternative adenovirus receptor and that integrin-activating strategies may improve the efficacy of recombinant adenoviruses as vectors for gene therapy.
Collapse
Affiliation(s)
- E Davison
- Department of Allergy and Respiratory Medicine, Guy's Hospital, London, United Kingdom
| | | | | | | | | |
Collapse
|
48
|
|
49
|
Bailey SM, Knox RJ, Hobbs SM, Jenkins TC, Mauger AB, Melton RG, Burke PJ, Connors TA, Hart IR. Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy. Gene Ther 1996; 3:1143-50. [PMID: 8986441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The most commonly employed 'suicide' gene/prodrug system used in cancer gene therapy is the herpes simplex virus thymidine kinase (HSVtk)/ganciclovir system. We have examined the efficacy of an alternative approach utilising the E. coli nitroreductase B enzyme with CB1954 and a variety of other prodrugs. V79 cells transfected with a nitroreductase expression vector were up to 770-fold more sensitive to CB1954 than control non-expressing cells. In general other prodrugs which were found by HPLC to act as substrates for purified E. coli nitroreductase also exhibited increased cytotoxicity against the nitroreductase-expressing cells, although this correlation was not absolute. In particular nitrofurazone (97-fold) and additional aromatic nitro-compounds (nine- to 50-fold) showed a large differential whereas the quinones and the antimetabolite, B-FU, were less effective (< three-fold). The results support the possibility of using nitroreductase and CB1954 for 'suicide gene' therapy and in addition suggest that alternative prodrugs, such as nitrofurazone, warrant further investigation in this novel approach.
Collapse
Affiliation(s)
- S M Bailey
- Richard Dimbleby Department of Cancer Research, Rayne Institute, St Thomas' Hospital, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Metastasis is the major cause of death in cancer patients. Our understanding of the molecular genetic and biologic events that contribute to tumor cell dissemination has increased considerably over the last decade. It is clear that close anatomic and temporal cooperation between cellular adhesion molecules, extracellular matrix-degrading proteases, and tumor vascularization is an essential component of the metastatic behavior of cancer cells. With this improved understanding have come novel antimetastatic therapies targeting distinct molecules and steps in the metastatic cascade. Here, we review the role of matrix-degrading enzymes, changes in cellular adhesive capacity, and tumor angiogenesis during cancer spread.
Collapse
Affiliation(s)
- A Ahmad
- Richard Dimbleby Department of Cancer Research/ICRF, Rayne Institute, UMDS, St. Thomas' Hospital, London, UK
| | | |
Collapse
|